Dr. Hauser earned his PhD in Molecular Genetics from University of California at Irvine. Following postdoctoral training at UC Berkeley, Dr. Hauser was recruited to the Sanford-Burnham faculty in 1989, and was promoted to Associate Professor in 1996. In 2005, he became an adjunct faculty member and assumed a full-time administrative role. Dr. Hauser currently serves as Vice President for Scientific Resources, and as Cancer Center Associate Director, Shared Resources, overseeing Sanford Burnham Prebys’ Shared Resource operations, scientific equipment, and scientific regulatory compliance.
Leadership Type: Scientific
A career history of fundamental discovery and translational research in immunology has guided Dr. Ware to identify new drug targets and develop novel therapeutics. Dr. Ware’s career in immunology and virology began in 1982 when he became a Professor at the University of California, Riverside’s Division of Biomedical Sciences. In 1996, he joined the La Jolla Institute for Immunology in San Diego as Head of the Division of Molecular Immunology. Professor Ware joined Sanford Burnham Prebys Medical Discovery Institute in 2010, serving as the Director of the Infectious and Inflammatory Disease Center and Adjunct Professor of Biology at the University of California at San Diego. He is currently the Director of the Laboratory of Molecular Immunology, which focuses on discovering and designing immunotherapeutics.
As an educator, he taught medical students immunology and virology. He trained over 60 postdoctoral fellows and graduate students who chose careers in research in academic and pharmaceutical science, patent law, or teaching.
Dr. Ware advises scientific panels and review boards for the National Institutes of Health and serves on the scientific advisor boards for the Allen Institute for Immunology and the Arthritis National Research Foundation. Scientific advisor with several biotechnology and pharmaceutical companies on immunotherapy for cancer and autoimmune diseases using innovative approaches to target discovery and drug development.
Dr. Ware’s research program is dedicated to unraveling the intricate intercellular communication pathways that govern immune responses. His work, which centers on cytokines in the Tumor Necrosis Factor (TNF) Superfamily, particularly those that regulate cell survival and death in response to viral pathogens, spans the domains of cancer,autoimmune and infectious diseases.
At Sanford Burnham Prebys, Dr. Ware is pivotal in promoting the translation of the faculty’s scientific discoveries. His efforts have led to the Institute’s reputation as a productive and preferred partner in collaborations with Pharma, including multi-year research and drug development projects with Eli Lilly and Avalo Therapeutics. His success translating fundamental knowledge into rational drug design has led to three novel therapeutics targeting inflammatory pathways, currently in clinical trials.
Education
- 1981-1982: T cell Immunology, Dana-Farber Cancer Institute of Harvard Medical School in Boston, MA. Tim Springer and Jack Strominger, advisors.
- 1979-1981: Biochemistry of Complement, University of Texas Health Science Center, San Antonio, TX. W Kolb, advisor
- 1974-1979: PhD in Molecular Biology and Biochemistry from the University of California, Irvine; Gale Granger, PhD mentor.
Honors and Recognition
- Distinguished Fellow, American Association of Immunologists
- Honorary Lifetime Membership Award International Cytokine and Interferon Society
- Hans J. Muller-Eberhardt Memorial Lecture
- Biotech All Star, San Diego Padres Award
- “Pillars of Immunology” discovery of the Lymphotoxin-b Receptor, published in Science
- Outstanding Alumnus, Ayala School of Biological Sciences, University of California, Irvine
- National MERIT Award R37 (10 years), National Institute of Allergy and Infectious Disease, NIH
- National Research Service Award, NIH Postdoctoral Fellowship
Evan Y. Snyder earned his MD and PhD (in neuroscience) from the University of Pennsylvania in 1980 as a member of NIH’s Medical Scientist Training Program (MSTP). He had also studied psychology and linguistics at the University of Oxford. After moving to Boston in 1980, he completed residencies in pediatrics and neurology as well as a clinical fellowship in Neonatal-Perinatal Medicine at Children’s Hospital-Boston, Harvard Medical School. He also served as Chief Resident in Medicine (1984-1985) and Chief Resident in Neurology (1987) at Children’s Hospital-Boston. In 1989, he became an attending physician in the Department of Pediatrics (Division of Newborn Medicine) and Department of Neurology at Children’s Hospital-Boston, Harvard Medical School. From 1985-1991, concurrent with his clinical activities, he conducted postdoctoral research as a fellow in the Department of Genetics, Harvard Medical School. In 1992, Dr. Snyder was appointed an instructor in neurology (neonatology) at Harvard Medical School and was promoted to assistant professor in 1996. He maintained lab spaces in both Children’s Hospital-Boston and at Harvard Institutes of Medicine/Beth-Israel Deaconess Medical Center. In 2003, Dr. Snyder was recruited to Sanford Burnham Prebys as Professor and Director of the Program in Stem Cell and Regenerative Biology. He then inaugurated the Stem Cell Research Center (serving as its founding director) and initiated the Southern California Stem Cell Consortium. Dr. Snyder is a Fellow of the American Academy of Pediatrics (FAAP). He also received training in Philosophy and Linguistics at Oxford University.
Select Publications
Showing 3 of 3Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis.
Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson’s disease.
Neural stem cells implanted into MPTP-treated monkeys increase the size of endogenous tyrosine hydroxylase-positive cells found in the striatum: a return to control measures.
Pier Lorenzo Puri earned his MD at the University of Rome “la Sapienza” in 1991. Dr. Puri completed his internship in Internal Medicine at the hospital “Policlinico Umberto I” (Rome) from 1992 to 1997, and defended an experimental thesis on the vascular effects of angiotensin II to graduate as Specialist in Internal medicine at the University of Rome “la Sapienza” in 1997. During this time he was frequently working at the Freien University of Berlin, as visiting scientist at the Deprtment of Biochemistry and Molecular Biology, to perform experiments of protein and DNA microinjection in cultured cells. Dr. Puri trained as a post-doctoral fellow at the University of California San Diego (UCSD), in the department of Cell Biology, under the supervision of Dr. Wang, from 1997 to 2001. He was appointed as Staff Scientist at the Salk Institute (La Jolla) in 2001, and became an Assistant Telethon Scientist at the Dulbecco Telethon Institute in Rome in 2002. He was upgraded to Associate Telethon Scientist at the Dulbecco Telethon Institute in Rome since 2007 and became Senior Telethon Scientist, Dulbecco Telethon Institute, in 2012, but declined this position. Dr. Puri joined Sanford Burnham Prebys as an Assistant Professor in 2004. He has been promoted to Associate Professor in 2010 and full Professor in 2015. From 2008 to 2016 Dr. Puri served as Adjunct Professor of Pediatrics at the University of California, San Diego. From 2008 to 2013 Dr Puri was an Associate Member of Sanford Children’s Health Research Center. Dr Puri has been Director of the laboratory of Epigenetics and Regeneration at Fondazione S. Lucia, Roma, Italy, but stepped down this position since 2019.
Education
University of California San Diego, Postdoctoral, Department of Biology
University of Rome La Sapienza, PhD, Internal Medicine
University of Rome La Sapienza, MD, Internal Medicine
University of Rome La Sapienza, Undergraduate, Internal Medicine
Other Appointments
2020-2024: Member of the Science Advisory Board (SAB) European Commission-funded Consortium BIND (Brain Involvement In Dystrophinopathies)
2015-2019: Standing Member, NIH Study Section (SMEP)
2010-present: Member of Editorial Board of Skeletal Muscle
Select Publications
Showing 3 of 3p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci.
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors.
Transcription Factor-Directed Re-wiring of Chromatin Architecture for Somatic Cell Nuclear Reprogramming toward trans-Differentiation.
Jamey Marth is a Professor at Sanford Burnham Prebys. He has also been Director of the Center for Nanomedicine at the University of California Santa Barbara and Professor in the Department of Molecular, Cellular, and Developmental Biology. Dr. Marth received a PhD degree in Pharmacology from the University of Washington where he trained in the laboratories of Roger M. Perlmutter and Edwin G. Krebs. Dr. Marth’s previous positions included Professor of Medical Genetics at the Biomedical Research Center, University of British Columbia; Professor of Cellular and Molecular Medicine at the University of California San Diego; and Investigator of the Howard Hughes Medical Institute.
Education
1987: PhD, University of Washington, Pharmacology
1984: BS, University of Oregon, Genetics and Chemistry
Honors and Recognition
2017: Karl Meyer Award, Society for Glycobiology
2009-2020: John Carbon Chair in Biochemistry and Molecular Biology
2009-2019: Duncan and Suzanne Mellichamp Chair in Systems Biology
2009: Julius Stone Lectureship Award: Society for Investigative Dermatology
1995-2009: Investigator Award, Howard Hughes Medical Institute
1991-1995: Faculty Scholarship, The Medical Research Council of Canada
Select Publications
Showing 1 of 1Dr. Randal Kaufman previously served as professor of Biological Chemistry and Internal Medicine and Howard Hughes Medical Research Institute investigator at the University of Michigan Medical School. He received his PhD in pharmacology from Stanford University, where he studied gene amplification as a mechanism by which cells become resistant to anticancer agents. He was a Helen Hay Whitney fellow with Nobel Laureate Dr. Phillip Sharp at the Center for Cancer Research at the Massachusetts Institute of Technology (M.I.T.), where he developed gene transfer technologies based on gene amplification and expression in mammalian cells. He did his postdoctoral work at the Center for Cancer Research at M.I.T. In the 1980s, Dr. Kaufman’s experience with gene transfer and engineering led him to become a founding scientist at Genetics Institute Inc., where he engineered mammalian cells for high-level expression of therapeutic proteins, such as clotting factors that are now used to treat individuals with hemophilia. Dr. Kaufman joined Sanford Burnham Prebys in 2011.
Education
Postdoctoral, Center for Cancer Research, M.I.T.
PhD, Stanford University
B.A., University of Colorado
Other Appointments
7/2011 – Present Adjunct Professor, Department of Biological Chemistry, University of Michigan, Ann Arbor, MI
Honors and Recognition
2006: AAAS Fellow
2000: Distinguished Investigator Award-MI Hemophilia Society
1999: Investigator Recognition Award, International Society of Thrombosis and Haemostasis
1998: International Association Francaise Des Hemophiles Award
1993: Dr. Murray Thelin Award
Dr. Jackson brings many years of drug discovery and development experience to Prebys Center. Prior to joining Sanford Burnham Prebys in 2009, Dr. Jackson spent 15 years working within Johnson & Johnson’s pharmaceutical research organization. He managed cross-disciplinary teams of scientists focused on discovering chemical leads and clinical candidates directed at novel first-in-class drug targets. In 1999, he took on the role of vice president of discovery research at Johnson & Johnson’s La Jolla, California location, where he establish a state-of-the-art drugs discovery institute. As site head, Dr. Jackson oversaw all aspects of the new institute, from building design to hiring the staff of 300 scientists. In 2001 Dr. Jackson’s responsibility was expanded and as senior vice president of drug discovery at Johnson & Johnson Pharmaceutical Research and Development (U.S.) he was responsible > 800 hundred drug discovery scientists spread over five sites in the United States. Under his leadership, this organization advanced many clinical candidates into development across 5 multiple therapeutic areas including CNS, Pain, Immunology, CV disease. In 2005, Dr. Jackson was appointed President of ALZA Corporation, a large biotech company acquired by Johnson & Johnson that focused on drug delivery. As president of ALZA, he was responsible for all aspects of a 1,200 person research and development organization, successfully gaining regulatory approval for multiple drug delivery products that leverage the Oros technology and a first in class iontophoretic patch for the treatment of pain.
Prior to his industry career Dr. Jackson was an assistant professor at The Scripps Research Institute, where he published widely in the fields of cell biology and immunology. His work included identification of motifs that direct intracellular targeting of proteins to subcellular organelles, and the relevance of this and protein folding to antigen presentation and processing in the immune system. He received his PhD from the Department of Biochemistry at the University of Dundee in Scotland.
Career Highlights
- Managed (2009-2012) and then lead as P.I (2013-2014), Sanford Burnham’s NIH funded U54 grant Molecular libraries comprehensive screening center.
- Led the transformation of the Prebys center from a chemical biology and probe production organization to a full capable drug discovery operation generating first in class small molecule drug leads/NME’s.
- Instrumental in securing the Institutes first major multi-year, multi PI/project thematic translational collaboration with a pharmaceutical company.
- Instrumental in establishing the Florida Translational Research Program – a multi year contract from the department of health/State of Florida supporting Sanford Burnham Prebys translational drug discovery program in Orlando.
- Developed and executed “first of a kind” collaborative translational agreements with the Mayo clinic.
- Key member of the executive team that established a 10-year plan for the Institute that defined a path to sustainability. This plan was instrumental in securing an anonymous donation to the Institute of $275MM in January 2014.
- Established a pipeline of first in class therapeutics leads, the first product of this pipeline was licensed to Daiichi Sankyo in 2015.
- Key interface between the Institute and philanthropist Conrad Prebys, which resulted in a $100MM donation to the Institute in 2015.
- Instrumental is establishing a regional drug discovery effort for Alzheimer’s disease in collaboration with Alzheimer’s San Diego, Mayor’s office San Diego and SD County Supervisor.
Dr. Freeze earned his PhD from the University of California, San Diego in 1976. Subsequently he held fellowships in Biology, Medicine and Neurosciences later joined the faculty at the same institution. In 1988 Dr. Freeze was recruited to Sanford Burnham Prebys.
Watch: Our inspiration for CDG research
Watch: Para-equestrian with rare disorder meets Olympian in San Diego
Watch: “Miracle:” Uridine at 2 days and 5.5 months
Select Publications
Showing 3 of 3Dr. Commisso’s doctoral studies were focused on various aspects of endocytosis pertaining to Notch signal transduction. Specifically, he analyzed the role of an endocytic protein known as Neuralized, which functions in the internalization of Notch ligands such as Delta and Jagged. As a doctoral trainee he gained extensive experience in cell biological and biochemical techniques pertaining to cellular trafficking. Subsequently, Dr. Commisso received postdoctoral training in pancreatic cancer at New York University School of Medicine. In that capacity he gained expertise in analyzing the complex signaling events mediated by oncogenic Ras during the initiation and progression of the disease. Additionally, he has expertise in the utilization of mouse models of pancreatic cancer including heterotopic/orthotopic xenografts, syngeneic heterotopic/orthotopic implantation and autochthonous models.
Select Publications
Showing 3 of 3Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma.
Macropinocytosis in Cancer-Associated Fibroblasts Is Dependent on CaMKK2/ARHGEF2 Signaling and Functions to Support Tumor and Stromal Cell Fitness.
Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells.
Dr. Bradley received her doctorate from the University of California Berkeley, in 1981 in studies of CD4 T cell subsets that regulate humoral immune responses. Her work on the regulation of CD4 T cells continued during her postdoctoral training at The Oregon Primate Research Center and at the University of California, San Diego where she was appointed Assistant Research Professor in 1991. It was at this time she developed NIH sponsored her research program on CD4 T cells and discovered the key associations between migration and function. She joined The Scripps Research institute as an Assistant Professor in 1996 where she expanded her work on CD4 T cells into the arena of autoimmunity and discovered the essential role of the cytokine, interleukin-7, in the regulation of CD4 cell homeostasis.
She joined the Sidney Kimmel Cancer Center in 2001 as an Associate Professor, and was promoted to Professor in 2005. She joined Sanford Burnham Prebys as a Professor in the Infectious and Inflammatory Diseases Center in 2009. Dr. Bradley is recognized as a key contributor in the field of CD4 T cell biology, is an invited speaker at many national and international meetings, and serves on several study sections for the NIH as well as the Welcome Trust, Medical Research Council, and the JDRF.